

Contents

Contributors

xiii

Preface

xvii

1. Glycan-based biomarkers for diagnosis of cancers and other diseases: Past, present, and future	1
Minghui Hu, Ying Lan, Alexander Lu, Xuexiao Ma, and Lijuan Zhang	
1. Introduction	2
2. The milestones in glycan-, glycoprotein-, and glycosylated protein-based biomarker discovery	6
3. Clinically used serum glucose-, glycan-, or glycoprotein-based biomarkers	10
4. Serum glycoprotein-derived N- and O-linked glycans as cancer biomarkers	12
5. Discussions and conclusions	16
Acknowledgment	18
Conflict of interest	18
References	18
2. Desialylation in physiological and pathological processes: New target for diagnostic and therapeutic development	25
Mohui Wei and Peng George Wang	
1. Introduction	26
2. Desialylation in physiology	31
3. Desialylation in pathology	38
4. Diagnostic and therapeutic development targeting on desialylation	44
5. Chemical desialylation	47
6. Conclusions and perspectives	50
References	50
3. Proteoglycans as miscommunication biomarkers for cancer diagnosis	59
Lingling Xu, Limin Tang, and Lijuan Zhang	
1. Introduction	60
2. GAG-based cancer biomarkers	62
3. Proteoglycan-based cancer biomarkers	65
4. GAG biosynthesis, degradation, and modifying enzymes	76

5. Concluding remarks	80
Acknowledgments	81
Conflicts of interest	81
References	81
4. Fucosylation in cancer biology and its clinical applications	93
Ming Shan, Dandan Yang, Huaqian Dou, and Lijuan Zhang	
1. Introduction	94
2. Fucosylation	95
3. Aberrant fucosylation in cancer	96
4. Role of fucosylation in carcinogenesis	103
5. Clinical potential and applications of changed fucosylation in cancer diagnosis and treatment	107
6. Conclusion and future perspectives	111
Acknowledgment	112
References	112
5. The sensitivity and specificity of serum glycan-based biomarkers for cancer detection	121
Yang Tang, Yidi Cui, Shufeng Zhang, and Lijuan Zhang	
1. Introduction	122
2. Clinically used cancer biomarkers developed based on hybridoma technology	123
3. Other clinically used cancer biomarkers	128
4. Conclusions and future perspectives	132
Acknowledgments	134
Conflicts of interest	134
References	134
6. Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past 6 years	141
Meng Zhang, Huaqian Dou, Dandan Yang, Ming Shan, Xiulian Li, Cui Hao, Yiran Zhang, Pengjiao Zeng, Yanli He, Yong Liu, Jing Fu, Wei Wang, Minghui Hu, Hui Li, Qingwu Tian, Shuhe Lei, and Lijuan Zhang	
1. Introduction	142
2. Methods	144
3. Results	145

4. Discussions and conclusions	159
Acknowledgments	160
Conflicts of interest	160
References	160
7. Serum SCCA levels in patients suffering cancers or other diseases	165
Dandan Yang, Jun Wang, and Lijuan Zhang	
1. Introduction	166
2. Serum SCCA level measurement	167
3. Serum SCCA levels in 39 human diseases and in healthy controls	168
4. Discussions and conclusions	172
Acknowledgments	173
Conflicts of interest	173
References	173
8. Increased serum CA724 levels in patients suffering gout vs cancers	177
Yiran Zhang, Meng Zhang, Xueshan Bai, Changgui Li, and Lijuan Zhang	
1. Introduction	178
2. Determination of serum CA724 levels	179
3. Serum CA724 levels in 37 different types of human diseases	180
4. Discussions and conclusions	183
Acknowledgments	184
Conflicts of interest	184
References	184
9. Serum CA50 levels in patients with cancers and other diseases	187
Ming Shan, Qingwu Tian, and Lijuan Zhang	
1. Introduction	188
2. Serum CA50 concentration measurement	190
3. Serum CA50 concentrations in 14 different types of human diseases	191
4. Discussions and conclusions	195
Acknowledgments	196
Conflicts of interest	196
References	196
10. Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases	199
Yanli He, Haijun Lu, and Lijuan Zhang	
1. Introduction	200

2. Determination of serum AFP concentration/serum AFP activity measurement	202
3. Serum AFP levels in 47 different types of diseases	203
4. Discussions and conclusions	207
Acknowledgments	209
Conflicts of interest	209
References	209
11. Serum CEA levels in 49 different types of cancer and noncancer diseases	213
Cui Hao, Guoqing Zhang, and Lijuan Zhang	
1. Introduction	214
2. Serum CEA level measurement	217
3. Serum CEA activities in 49 human diseases	218
4. Discussions and conclusions	222
Acknowledgment	224
Conflict of interest	224
Reference	224
12. CA242 as a biomarker for pancreatic cancer and other diseases	229
Huaiqian Dou, Guirong Sun, and Lijuan Zhang	
1. Introduction	230
2. Serum CA242 measurement	232
3. Serum CA242 levels in 27 diseases	232
4. Conclusion and discussion	235
Acknowledgment	237
Conflict of interest	237
References	237
13. Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers	241
Meng Zhang, Yiran Zhang, Jing Fu, and Lijuan Zhang	
1. Introduction	242
2. Determination of serum CA125 levels	243
3. Serum CA125 levels in 40 different types of human diseases	244
4. Conclusions and discussions	247
Acknowledgments	250
Conflict of interest	250
References	250

14. Serum CA199 levels are significantly increased in patients suffering from liver, lung, and other diseases	253
Pengjiao Zeng, Hui Li, Yulong Chen, Haitao Pei, and Lijuan Zhang	
1. Introduction	254
2. Serum CA199-level measurement	256
3. Serum CA199 levels in 47 human diseases and in healthy controls	257
4. Discussions and conclusions	261
Acknowledgments	262
Conflicts of interest	262
References	262
15. Serum CA153 as biomarker for cancer and noncancer diseases	265
Xiulian Li, Yan Xu, and Lijuan Zhang	
1. Introduction	266
2. Serum CA153 measurement	267
3. Serum CA153 levels in 30 different types of diseases	268
4. Discussions and conclusions	272
Acknowledgments	273
Conflicts of interest	273
References	273
16. Fasting blood glucose levels in patients with different types of diseases	277
Qinghua Zhang, Gang Zhao, Nailong Yang, and Lijuan Zhang	
1. Introduction	278
2. FBG measurement	280
3. FBG levels in 64 different types of diseases	281
4. Discussions and conclusions	285
Acknowledgments	288
Conflicts of interest	288
References	288
17. HbA1c: High in acute cerebral infarction and low in brain trauma	293
Zhifeng Jiang, Jigang Wang, Peng Zhao, Lijuan Zhang, and Yunliang Guo	
1. Introduction	294
2. Methods for HbA1c measurement	296

3. HbA1c levels in 36 different types of diseases	297
4. Discussions and conclusions	301
Acknowledgment	303
Conflict of interest	303
References	303
18. Glycated albumin level is significantly decreased in patients suffering nephrotic syndrome	307
Zhe Wang, Guangqun Xing, and Lijuan Zhang	
1. Introduction	308
2. Methods for GA measurement	309
3. GA levels in 57 different types of diseases	310
4. Discussions and conclusions	314
Acknowledgment	316
Conflict of interest	316
References	316
19. Glycated serum proteins: High in pancreatic cancer and low in preeclampsia	321
Xueling Wang, Rui Zhang, Lijuan Zhang, and Zibin Tian	
1. Introduction	322
2. Methods for GSP measurement	323
3. GSP levels in 61 different types of diseases	324
4. Discussions and conclusions	329
Acknowledgments	330
Conflicts of interest	331
References	331
20. The serum SA levels are significantly increased in sepsis but decreased in cirrhosis	335
Xiaodan Huang, Qin Yao, Lijuan Zhang, and Zibin Tian	
1. Introduction	336
2. Serum/plasma SA concentration measurement	338
3. Serum SA levels in 64 different types of diseases	339
4. Discussions and conclusions	343
Acknowledgment	345
Conflict of interest	345
References	346

21. Serum α-L-fucosidase activities are significantly increased in patients with preeclampsia	349
Meng Zhang, Lin Wang, Haiping Zhang, Juan Cong, and Lijuan Zhang	
1. Introduction	350
2. Serum α -L-fucosidase activity measurement	353
3. Serum α -L-fucosidase activities in 64 human diseases	354
4. Discussions and conclusions	359
Acknowledgment	360
Conflict of interest	360
References	360
22. Glucuronidated bilirubin: Significantly increased in hepatic encephalopathy	363
Limin Tang, Meng Zhang, Xiulian Li, and Lijuan Zhang	
1. Introduction	364
2. Serum bilirubin measurement	366
3. Serum direct bilirubin levels in 38 different types of human diseases and healthy controls	367
4. Discussions and conclusions	372
Acknowledgment	373
Conflict of interest	373
References	373
23. Serum PSA levels in patients with prostate cancer and other 33 different types of diseases	377
Yanyun Gao, Meng Zhang, Xiulian Li, Pengjiao Zeng, Peitao Wang, and Lijuan Zhang	
1. Introduction	378
2. Determination of serum PSA levels	379
3. Serum PSA levels in 33 different types of human diseases and healthy controls	380
4. Discussions and conclusions	386
Acknowledgments	388
Conflicts of interest	388
References	388
Index	391